Interleukin-17: a potential therapeutic target in COVID-19

In a recent review, Ye and colleagues discussed in this journal the inflammatory response mechanisms underlying the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its implications for therapy1, consistently with the current worldwide necessity of understanding and finding clinical therapies for the disease as it has been declared by the World Health Organization (WHO) a Public Health Emergency of International Concern, that to date has triggered the infection of more than 5 million people and over 300.000 deaths around the world.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research